Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Rizzo A, Mollica V, Santoni M, Massari F. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clin Genitourin Cancer. 2022 10; 20(5):482-487.
-
Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol. 2022 Feb; 18(6):739-748.
-
Aronowitz J, Ding L, Yates J, Zong Y, Zheng L, Jiang Z, Yancey J, Mittal K, Fitzgerald TJ. Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates. Am J Clin Oncol. 2021 05 01; 44(5):175-180.
-
Sun T, Hutchinson L, Tomaszewicz K, Caporelli ML, Meng X, McCauley K, Fischer AH, Cosar EF, Cornejo KM. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathol. 2021 07; 129(7):537-547.
-
Rizzo A, Mollica V, Massari F. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus. 2022 Jan; 8(1):152-159.
-
Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. Eur Urol. 2021 01; 79(1):e17-e19.
-
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.
-
Cimadamore A, Scarpelli M, Massari F, Eckstein M, Gevaert T, Cheng L, Lopez-Beltran A, Montironi R. Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view. Expert Opin Biol Ther. 2020 06; 20(6):539-544.
-
Wang J, Greenberg S, Yates J. Lynch Syndrome-associated Upper Tract Urothelial Carcinoma. Urology. 2018 Nov; 121:19-21.
-
Buti S, Ciccarese C, Iacovelli R, Bersanelli M, Scarpelli M, Lopez-Beltran A, Cheng L, Montironi R, Tortora G, Massari F. Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: part 2 - prostate and bladder cancer. Future Oncol. 2016 Sep; 12(17):1971-4.